Biscayne NeuroTherapeutics
Biscayne Pharmaceuticals discovers and develops novel therapies based on growth hormone-releasing hormone (GHRH) analogs.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD252m (Public information from Sep 2018)
Miami Florida (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$3.0m | Series B | ||
$185m Valuation: $185m | Acquisition | ||
| Total Funding | CAD4.1m | ||
Related Content
Recent News about Biscayne NeuroTherapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.